Robert J Arceci
Overview
Explore the profile of Robert J Arceci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
3137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montoya J, Turnidge M, Wai D, Patel A, Lee D, Gokhale V, et al.
BMC Cancer
. 2019 Dec;
19(1):1251.
PMID: 31881855
Background: Acute Myeloid Leukemia (AML) is a malignancy of myeloid precursor cells that arise from genomic alterations in the expression of key growth regulatory genes causing cells to assume an...
2.
Azorsa D, Lee D, Wai D, Bista R, Patel A, Aleem E, et al.
Pediatr Blood Cancer
. 2018 May;
65(9):e27237.
PMID: 29768711
Patients with Langerhans cell histiocytosis (LCH) harbor BRAF V600E and activating mutations of MAP2K1/MEK1 in 50% and 25% of cases, respectively. We evaluated a patient with treatment-refractory LCH for mutations...
3.
Gore L, Triche Jr T, Farrar J, Wai D, Legendre C, Gooden G, et al.
Clin Epigenetics
. 2017 Oct;
9:108.
PMID: 29034009
Background: Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. Accordingly,...
4.
Bista R, Lee D, Pepper O, Azorsa D, Arceci R, Aleem E
J Exp Clin Cancer Res
. 2017 Feb;
36(1):22.
PMID: 28143565
Background: Children with Down syndrome (DS) have increased risk for developing AML (DS-AMKL), and they usually experience severe therapy-related toxicities compared to non DS-AMKL. Refractory/relapsed disease has very poor outcome,...
5.
Arceci R, Allen C, Dunkel I, Jacobsen E, Whitlock J, Vassallo R, et al.
Pediatr Blood Cancer
. 2016 Nov;
64(5).
PMID: 27804235
Background: Langerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and...
6.
Egeler R, Katewa S, Leenen P, Beverley P, Collin M, Ginhoux F, et al.
Pediatr Blood Cancer
. 2016 Jun;
63(10):1704-12.
PMID: 27314817
Langerhans cell histiocytosis (LCH) remains a poorly understood disorder with heterogeneous clinical presentations characterized by focal or disseminated lesions that contain excessive CD1a+ langerin+ cells with dendritic cell features known...
7.
Samis J, Lee P, Zimmerman D, Arceci R, Suttorp M, Hijiya N
Pediatr Blood Cancer
. 2016 Apr;
63(8):1332-8.
PMID: 27100618
Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy...
8.
Elmoneim A, Heuston E, Wai D, Triche T, Arceci R
Anticancer Res
. 2016 Feb;
36(2):691-6.
PMID: 26851026
Background: The search for synergistic drug combinations is critical to the treatment of drug-resistant cancer, such as acute myeloid leukemia (AML). Characterizing RNA expression associated with 5-aza-2'-deoxycytidine (DAC) and 1-h-D-arabinofuranosylcytosine...
9.
Imashuku S, Arceci R
Hematol Oncol Clin North Am
. 2015 Oct;
29(5):875-93.
PMID: 26461148
Diseases of the central nervous system (CNS) are common in patients with Langerhans cell histiocytosis (LCH). Besides active LCH lesions, neurodegenerative (ND) lesions of the cerebellum and/or basal ganglia may...
10.
Cooper S, Arceci R, Gamper C, Teachey D, Schafer E
Pediatr Blood Cancer
. 2015 Oct;
63(2):358-60.
PMID: 26452062
Sinus histiocytosis with massive lymphadenopathy (SHML), or Rosai-Dorfman disease (RDD), is a non-neoplastic, lymphoproliferative disorder that usually resolves spontaneously or with minimal conventional chemotherapy. Rarely, SHML can be associated with...